Pan Xueyin, Wang Qiang, Sun Beicheng
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Provincial Innovation Institute for Pharmaceutical Basic Research, Hefei, Anhui, China; Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, Anhui, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Provincial Innovation Institute for Pharmaceutical Basic Research, Hefei, Anhui, China; Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, Hefei, Anhui, China.
Biochim Biophys Acta Rev Cancer. 2024 Nov;1879(6):189231. doi: 10.1016/j.bbcan.2024.189231. Epub 2024 Nov 28.
Neutrophils, the most abundant leukocyte population in circulation, play a crucial role in detecting and responding to foreign cells, such as pathogens and tumor cells. However, the impact of neutrophils on cancer pathogenesis has been overlooked because of their short lifespan, terminal differentiation, and limited transcriptional activity. Within the tumor microenvironment (TME), neutrophils can be influenced by tumor cells or other stromal cells to acquire either protumor or antitumor properties via the cytokine environment. Despite progress in neutrophil-related research, a comprehensive understanding of tissue-specific neutrophil diversity and adaptability in the TME is still lacking, which poses a significant obstacle to the development of neutrophil-based cancer therapies. This review evaluated the current studies on the dual roles of neutrophils in cancer progression, emphasizing their importance in predicting clinical outcomes, and explored various approaches for targeting neutrophils in cancer treatment, including their potential synergy with cancer immunotherapy.
中性粒细胞是循环中数量最多的白细胞群体,在检测和应对外来细胞(如病原体和肿瘤细胞)方面发挥着关键作用。然而,由于其寿命短、终末分化和转录活性有限,中性粒细胞对癌症发病机制的影响一直被忽视。在肿瘤微环境(TME)中,中性粒细胞可受肿瘤细胞或其他基质细胞影响,通过细胞因子环境获得促肿瘤或抗肿瘤特性。尽管中性粒细胞相关研究取得了进展,但仍缺乏对TME中组织特异性中性粒细胞多样性和适应性的全面了解,这对基于中性粒细胞的癌症治疗发展构成了重大障碍。本综述评估了目前关于中性粒细胞在癌症进展中的双重作用的研究,强调了它们在预测临床结果中的重要性,并探讨了在癌症治疗中靶向中性粒细胞的各种方法,包括它们与癌症免疫疗法的潜在协同作用。